BioDrugs

, Volume 15, Issue 9, pp 573–584

Management of Hepatitis C Virus-Related Arthritis

Therapy in Practice

Abstract

Hepatitis C virus (HCV) infection is often associated with extrahepatic manifestations among which arthropathy is common, affecting up to 20% of HCV-infected individuals. This arthropathy is to be distinguished from the more superficially prominent myalgias and fatigue. HCV-related arthritis is commonly presented as rheumatoid-like, symmetrical inflammatory polyarthritis involving mainly small joints, or, less commonly, as mono-or oligoarthritis, usually of the large joints. HCV arthritis usually runs a relatively benign course that, in contrast to ‘true’ rheumatoid arthritis (RA), is typically non-deforming and is not associated with articular bony erosions. In addition, unlike ‘classic’ RA, erythrocyte sedimentation rate is elevated only in about half of the patients and subcutaneous nodules are absent. In about two-thirds of the affected individuals morning stiffness may be severe, resolving after more than an hour. Several pathogenetic mechanisms may be involved: HCV arthritis may be part of the syndrome of mixed cryoglobulinaemia, or may be directly or indirectly mediated by HCV. Such possible, but yet not proven, mechanisms include direct invasion of synovial cells by the virus eliciting local inflammatory response, cytokine-induced disease or immune complex disease, particularly in genetically susceptible individuals.

The diagnosis of HCV arthritis in patients with positive rheumatoid factor and chronic inflammatory polyarthritis may be difficult. Positive HCV antibody and HCV RNA, and the absence of bony erosions, subcutaneous nodules and antikeratin antibodies, may be useful in distinguishing between HCV-related arthritis and RA. The optimal treatment of HCV-related arthritis has not yet been established. Concerns may be raised regarding the use of immunosuppressive or potentially hepatotoxic drugs. However, it may be suggested that once the diagnosis of HCV-associated arthritis is made, combination antiviral treatment with interferon-α and ribavirin should be initiated as part of the therapeutic armamentarium. Low dose oral corticosteroids, nonsteroidal anti-inflammatory drugs, hydroxychloroquine or sulfasalazine in addition to the antiviral therapy can be used to control arthritis-related symptoms. Some patients may need long term anti-inflammatory treatment in various combinations, along with antiviral therapy. In patients with severe, disabling or life-threatening cryoglobulinaemiarelated symptoms refractory to antiviral or anti-inflammatory treatment, high dose corticosteroids (including pulse therapy) and/or plasmapheresis may be needed.

References

  1. 1.
    Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–4PubMedCrossRefGoogle Scholar
  2. 2.
    Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatology 1992; 15: 382–6CrossRefGoogle Scholar
  3. 3.
    Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 9: 621–4PubMedGoogle Scholar
  4. 4.
    Bichard P, Ounanian A, Girard M, et al. High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobulinemia. J Hepatol 1994; 21: 58–63PubMedCrossRefGoogle Scholar
  5. 5.
    Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122: 169–73PubMedGoogle Scholar
  6. 6.
    Ivanovski M, Silversti F, Pozzato G, et al. Somatic mutation, clonal diversity, and preferential expression of the VH 51pl/ VL kv325 immunoglobulin gene combination in hepatitis C virus associated immunocytomas. Blood 1998; 91: 2433–42PubMedGoogle Scholar
  7. 7.
    Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938–41PubMedCrossRefGoogle Scholar
  8. 8.
    Euller-Ziegler L, Chami H, Grisot C, et al. Rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection [abstract]. Arthritis Rheum 1995; Suppl. 38: S200Google Scholar
  9. 9.
    Garcia-Monforte A, Romero M, de Diego A, Rivera J. Rheumatic and autoimmune manifestations in chronic hepatitis C virus infection [abstract] Arthritis Rheum 1995; Suppl. 38: S200Google Scholar
  10. 10.
    Perrot S, Job-deslandre C, Puechal X, et al. Serological study of HCV infection in 4 groups of cases of polyarthritis [abstract]. Arthritis Rheum 1995; Suppl. 38: S200Google Scholar
  11. 11.
    Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998; 28: 107–13PubMedCrossRefGoogle Scholar
  12. 12.
    Zuckerman E, Keren D, Rozenbaum M, et al. HCV-related arthritis: characteristics and response to therapy with interferon alfa. Clin Exp Rheumatol 2000; 18: 579–84PubMedCrossRefGoogle Scholar
  13. 13.
    Barkhuizen A, Rosen HR, Wolf S, et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 Hepatology clinic patients. Am J Gastroenterol 1999; 94: 1355–60PubMedGoogle Scholar
  14. 14.
    Barkhuizen A, Schoepflin GS, Bennett R. Fibromyalgia: a prominent rheumatic problem in chronic hepatitis C infection. A report of 12 patients. Clin Rheumatol 1996; 2: 180–4CrossRefGoogle Scholar
  15. 15.
    Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med 1997; 157: 2497–500PubMedCrossRefGoogle Scholar
  16. 16.
    Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic maifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204–12PubMedCrossRefGoogle Scholar
  17. 17.
    Sawada T, Hirohata S, Inoue T, et al. Development of rheumatoid arthritis after hepatitis C virus infection [letter]. Arthritis Rheum 1991; 34: 1620–1PubMedGoogle Scholar
  18. 18.
    Lovy MR, Starkebaum G, Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 1996; 23: 979–83PubMedGoogle Scholar
  19. 19.
    Ueno Y, Kinoshita R, Kishimoto I, et al. Polyarthritis associated with hepatitis C virus infection. Br J Rheumatol 1994; 33: 289–91PubMedCrossRefGoogle Scholar
  20. 20.
    Rosner I, Rozenbaum M, Zuckerman E, et al. Rheumatoid-like arthritis associated with hepatitis C. J Clin Rheumatol 1995; 1: 182–4PubMedCrossRefGoogle Scholar
  21. 21.
    Rivera J, Garcia-Monforte A, Pineda A, et al. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999; 26: 420–4PubMedGoogle Scholar
  22. 22.
    Arnett FC, Edworthy SM, Bloch DE, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24PubMedCrossRefGoogle Scholar
  23. 23.
    Ferri C, Marzo E, Longobardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132–6PubMedGoogle Scholar
  24. 24.
    Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, HCV-related mixed cryoglobulinemia with ribavirin and interferon alfa. J Rheumatol 2000; 27: 2172–8PubMedGoogle Scholar
  25. 25.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterolgy 1995; 108: 157–64CrossRefGoogle Scholar
  26. 26.
    Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91: 2062–6PubMedGoogle Scholar
  27. 27.
    Shapiro S, Gershtein V, Elias N, et al. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alfa (IFN-alfa) treatment. Clin Exp Immunol 1998; 114: 55–60PubMedCrossRefGoogle Scholar
  28. 28.
    Ohta N, Nishimura YK, Tanimoto K, et al. Association between HLA and Japanese patients with rheumatoid arthritis. Hum Immunol 1982; 5: 123–32PubMedCrossRefGoogle Scholar
  29. 29.
    Kessel A, Rosner I, Zuckerman E, et al. Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis c infection. J Rheumatol 2000; 27: 610–2PubMedGoogle Scholar
  30. 30.
    Young BJ, Mallya RK, Leslie RD, et al. Anti-keratin antibodies in rheumatoid arthritis. BMJ 1979; 2: 97–9PubMedCrossRefGoogle Scholar
  31. 31.
    Kirstein H, Mathiesen KF. Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scand J Rheumatol 1987; 16: 331–8PubMedCrossRefGoogle Scholar
  32. 32.
    Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196–9PubMedGoogle Scholar
  33. 33.
    Lok ASF, Liang RHS, Chiu EKW, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182–8PubMedGoogle Scholar
  34. 34.
    Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematological malignancies. Cancer 1998; 83: 1224–30PubMedCrossRefGoogle Scholar
  35. 35.
    Kanamori H, Fukawa H, Maruta A, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992; 303: 109–11PubMedCrossRefGoogle Scholar
  36. 36.
    Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363–8PubMedCrossRefGoogle Scholar
  37. 37.
    Stiehm ER, Kronenberg LH, Rosenblatt HM, et al. Interferon: immunology and clinical significance. Ann Intern Med 1982; 96: 80–93PubMedGoogle Scholar
  38. 38.
    Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751–6PubMedCrossRefGoogle Scholar
  39. 39.
    Poynard T, Marcellin P, Lee S, et al. 1998. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32PubMedCrossRefGoogle Scholar
  40. 40.
    Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral induced macrophage production of TNF, IL-1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response. Hepatology 1996; 24: 235–9Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Liver Unit, Department of Internal Medicine ABnai Zion Medical CenterHaifaIsrael
  2. 2.Rheumatology UnitBnai Zion Medical CenterHaifaIsrael

Personalised recommendations